🔗 Visit the ClinicalTrials.gov page for NCT01750983
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. | J Leukoc Biol | 2013 | 1.90 |
| 2 | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. | Oncoimmunology | 2014 | 1.22 |
| 3 | Advances in immunotherapy for treatment of lung cancer. | Cancer Biol Med | 2015 | 0.95 |
| 4 | Checkpoint modulation in melanoma: an update on ipilimumab and future directions. | Curr Oncol Rep | 2013 | 0.94 |
| 5 | Trial Watch: Lenalidomide-based immunochemotherapy. | Oncoimmunology | 2013 | 0.94 |
| 6 | Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". | Toxins (Basel) | 2014 | 0.92 |
| 7 | The past, present and future of immunotherapy against tumor. | Transl Lung Cancer Res | 2015 | 0.85 |
| 8 | Therapeutic challenges in renal cell carcinoma. | Am J Clin Exp Urol | 2015 | 0.80 |
| 9 | Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. | J Immunol Res | 2015 | 0.78 |